Please provide your email address to receive an email when new articles are posted on . Steroid alternatives should be considered for patients with bullous pemphigoid, who are most likely to be ...

Researchers identified three different clusters of bullous pemphigoid, the most common autoimmune blistering disorder, according to a study published in the Journal of American Academy of Dermatology.

COVID-19 infection increases the risk for autoimmune blistering diseases (AIBDs), specifically pemphigus and bullous pemphigoid, according to a study that also found that vaccination against COVID-19 ...

Older age and skin cancer history increase bullous pemphigoid risk in patients on immune checkpoint inhibitors. Study of 2,955 patients found 35 developed bullous pemphigoid, with 20 aged 70 or older.

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP BP is a chronic, ...

Anti-BP180 antibody levels demonstrated a moderate to strong correlation with the severity of bullous pemphigoid (BP), in a meta-analysis highlighting the potential of anti-BP180 as a tool to monitor ...

Dupixent may become the first targeted treatment for bullous pemphigoid in the U.S., pending FDA approval by June 2025. Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has accepted a ...